Efficiency of Biomarker-Driven Clinical Trial Designs.
作者信息
Freidlin Boris, Korn Edward L
机构信息
Boris Freidlin, PhD and Edward L. Korn, PhD, Biostatistics Branch, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
出版信息
J Clin Oncol. 2024 Apr 20;42(12):1454-1455. doi: 10.1200/JCO.23.02581. Epub 2024 Mar 4.
Abstract
摘要
相似文献
1
Efficiency of Biomarker-Driven Clinical Trial Designs.
J Clin Oncol. 2024 Apr 20;42(12):1454-1455. doi: 10.1200/JCO.23.02581. Epub 2024 Mar 4.
2
Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Br Med Bull. 2015 Jun;114(1):17-27. doi: 10.1093/bmb/ldv011. Epub 2015 Apr 28.
3
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
Curr Oncol Rep. 2011 Feb;13(1):42-9. doi: 10.1007/s11912-010-0144-x.
4
Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions.
JCO Precis Oncol. 2024 Jun;8:e2400116. doi: 10.1200/PO.24.00116.
5
Introduction to special issue on biomarker-based clinical trial designs in oncology.
Chin Clin Oncol. 2015 Sep;4(3):28. doi: 10.3978/j.issn.2304-3865.2015.09.05.
6
Biomarker-based trials in neuro-oncology.
Chin Clin Oncol. 2015 Sep;4(3):38. doi: 10.3978/j.issn.2304-3865.2015.09.04.
7
On Enrichment Strategies for Biomarker Stratified Clinical Trials.
J Biopharm Stat. 2018;28(2):292-308. doi: 10.1080/10543406.2017.1379532. Epub 2017 Oct 30.
8
Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.
Neuro Oncol. 2017 Jul 1;19(7):908-917. doi: 10.1093/neuonc/now312.
9
Advancing cancer drug development through precision medicine and innovative designs.
J Biopharm Stat. 2018;28(2):229-244. doi: 10.1080/10543406.2017.1402784. Epub 2017 Nov 27.
10
Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
Stat Med. 2018 Feb 28;37(5):687-709. doi: 10.1002/sim.7562. Epub 2017 Dec 4.
引用本文的文献
1
Two-to-One Randomization: Rarely Advisable.
JCO Oncol Pract. 2024 Dec;20(12):1555-1558. doi: 10.1200/OP.24.00217. Epub 2024 Jul 10.
本文引用的文献
1
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
J Clin Oncol. 2024 Jan 20;42(3):348-357. doi: 10.1200/JCO.23.00971. Epub 2023 Oct 26.
2
What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020).
BMJ Open. 2022 Oct 7;12(10):e064458. doi: 10.1136/bmjopen-2022-064458.
3
Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.
JCO Precis Oncol. 2019 Oct 24;3. doi: 10.1200/PO.19.00060. eCollection 2019.
4
Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?
J Natl Cancer Inst. 2020 Aug 1;112(8):773-778. doi: 10.1093/jnci/djz240.
5
How do you design randomised trials for smaller populations? A framework.
BMC Med. 2016 Nov 25;14(1):183. doi: 10.1186/s12916-016-0722-3.
6
The questionable use of unequal allocation in confirmatory trials.
Neurology. 2014 Jan 7;82(1):77-9. doi: 10.1212/01.wnl.0000438226.10353.1c. Epub 2013 Dec 4.
7
Biomarker enrichment strategies: matching trial design to biomarker credentials.
Nat Rev Clin Oncol. 2014 Feb;11(2):81-90. doi: 10.1038/nrclinonc.2013.218. Epub 2013 Nov 26.
8
Randomized clinical trials with biomarkers: design issues.
J Natl Cancer Inst. 2010 Feb 3;102(3):152-60. doi: 10.1093/jnci/djp477. Epub 2010 Jan 14.
9
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
J Clin Oncol. 2009 Aug 20;27(24):4027-34. doi: 10.1200/JCO.2009.22.3701. Epub 2009 Jul 13.
Zotero 插件